NASDAQ : ALVO
Alvotech — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Luxembourg
Last price 4.65 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.66B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.66B |
| Enterprise Value | 2.97B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 356.91M |
| Shares Outstanding | 356.91M |
| Shares Change (YoY) | +3.53% |
| Shares Change (QoQ) | +1.43% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 11.30% |
| Float | 140.83M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 46.09 |
| PS Ratio | 3.36 |
| Forward PS | 2.09 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.53 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 6.00 |
| EV / EBITDA | 39.20 |
| EV / EBIT | 56.94 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.65 |
| Quick Ratio | 0.79 |
| Debt / Equity | n/a |
| Debt / EBITDA | 15.91 |
| Debt / FCF | n/a |
| Interest Coverage | 0.33 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 2.19% |
| Return on Invested Capital (ROIC) | 4.31% |
| Return on Capital Employed (ROCE) | 4.15% |
| Weighted Average Cost of Capital (WACC) | 6.82% |
| Revenue Per Employee | $386,715 |
| Profits Per Employee | -$140,414 |
| Employee Count | 1,279 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 1.02 |
Taxes
| Measure | Value |
|---|
| Income Tax | 147.43M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -41.14% |
| 50-Day Moving Average | 5.32 |
| 200-Day Moving Average | 4.21 |
| Relative Strength Index (RSI) | 38.87 |
| Average Volume (20 Days) | 950,303 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.36M |
| Short Previous Month | 6.35M |
| Short % of Shares Out | 1.78% |
| Short % of Float | 4.52% |
| Short Ratio (days to cover) | 4.72 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 494.61M |
| Gross Profit | 300.04M |
| Operating Income | 52.14M |
| Pretax Income | -32.16M |
| Net Income | -179.59M |
| EBITDA | 75.73M |
| EBIT | 52.14M |
| Loss Per Share | -$0.61 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 142.75M |
| Total Debt | 1.45B |
| Net Cash | -1.31B |
| Net Cash Per Share | -$3.67 |
| Equity (Book Value) | -191.48M |
| Book Value Per Share | -0.54 |
| Working Capital | 213.79M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -198.70M |
| Capital Expenditures | -62.68M |
| Depreciation & Amortization | 23.60M |
| Net Borrowing | 190.22M |
| Free Cash Flow | -261.38M |
| FCF Per Share | -$0.73 |
Margins
| Measure | Value |
|---|
| Gross Margin | 60.66% |
| Operating Margin | 10.54% |
| Pretax Margin | -6.50% |
| Profit Margin | -36.31% |
| EBITDA Margin | 15.31% |
| EBIT Margin | 10.54% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.53% |
| Shareholder Yield | -3.53% |
| Earnings Yield | -13.08% |
| FCF Yield | -15.75% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.20 |
| Price Target Difference | 54.84% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 16.40% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |